Participants at OMERACT 8
May 10–14, 2006

Ade Adebajo, United Kingdom
Rieke Alten, Germany
Doug Altman, United Kingdom
Jane Angwin, United Kingdom
Marina Backhaus, Germany
Peter Balint, Hungary
Nick Bansback, Canada
Xenofon Baraliakos, Germany
Jil Beardmore, Canada
Dorcas Beaton, Canada
Jean-Claude Becker, United States
Michael Becker, United States
Frank Behrens, Germany
Miquel Belmonte-Serrano, Spain
Hein Bernelot Moens, Netherlands
Javier Berrios, United States
Anna Beutler, United States
Clifton Bingham, United States
Michael Binks, United Kingdom
Paul Bird, Australia
Jakob Bjorner, United States
Maarten Boers, Netherlands
Annelies Boonen, Netherlands
Pernille Boyesen, Norway
David L. Boyle, United States
Juergen Braun, Germany
Barry Bresnihan, Ireland
Peter Brooks, Australia
Piet Bruijnzeel, Netherlands
George Bruyn, Netherlands
Loreta Bukauskiene, Lithuania
Marc Buyse, Belgium
Jan Canvin, United States
Loreto Carmona, Spain
Sueli Carneiro, Brazil
Serena Carville, United Kingdom
W.M. Lesley Castro, United States
Alberto Cauda, Italy
R. Krishna Chaganti, United States
Eliza Chakravarty, United States
David Chandler, United Kingdom
David Chang, United States
Lan Chen, United States
Ernest Choy, United Kingdom
Philip Clements, United States
Bernard Combe, France
Philip Conaghan, United Kingdom
Peter Conway, United Kingdom
John Coombs, United States
Leslie Crofford, United States
Maria-Antonietta D’Agostino, France
Nicola Dalbeth, New Zealand
Vaune Davis, Canada
Aileen Davis, Ireland
Mirjam K. de Vries, Netherlands
Maarten de Wit, Netherlands
Cesar Diaz-Torne, Spain
Bernadus Dijkmans, Netherlands
Oliver Distler, Switzerland
Maxime Dougdos, France
Michael Drummond, United Kingdom
Kim Dupree-Jones, United States
N. Lawrence Edwards, United States
Bo Iannik Ejbjerg, Denmark
David Elashoff, United States
Maria Elf, Sweden
Reuben Escorpizo, Canada
Luis Espinoza, United States
Fabien Etchepare, France
Bruno Fautrel, France
David Felton, United States
Jose Luis Fernandez-Suero, Spain
Emilio Filipluccii, Italy
Axel Finckh, Switzerland
Oliver FitzGerald, Ireland
Ivan Foeldvari, Germany
James Fries, United States
Daniel Furst, United States
Sally Gallbraith, Australia
Frederique Gandjikakhch, France
Michael Gendreau, United States
Danielle M. Gerlag, Netherlands
Jon Giles, United States
Xavier Gittin, Switzerland
Dafna Gladman, Canada
Duncan Gordon, Canada
Simeon Grazio, Croatia
Peter Grimm, United States
Espen Haavardsholm, Norway
Hilde Berner Hammer, Norway
Gillian Hawker, Canada
Kirstie Haywood, United Kingdom
Mieke Hazes, Netherlands
Alison Heald, United States
Paul Healy, United Kingdom
Philip Helliwell, United Kingdom
Bernhard Hellmich, Germany
Karen Herlyn, Germany
Kay-Gerett Hermann, Germany
Sarah Hewlett, United Kingdom
Carol Hitchon, Canada
Ben Horgan, Australia
Mike Horton, United Kingdom
Jos Houbiers, Netherlands
Michael Hughes, United States
Doerte Huscher, Germany
Elaine Husni, United States
Annamaria Iagnocco, Italy
OMERACT 8 — 8th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials

OMERACT is an informal international network of health professionals that organizes meetings focused on outcome measurement across randomized controlled trials and longitudinal observational studies. OMERACT strives to improve outcome measures through a data-driven, iterative consensus process. OMERACT has a 5 member Executive Committee, with members from 3 continents, as well as a 15 member Scientific Advisory Committee composed of international opinion leaders from 9 countries.

We have started a third global cycle since 1992. We started in The Netherlands, visited Canada, Australia (twice), Mexico, France, the United States, and now Malta: a piece of European soil that was hotly contested in the last 2000 years. In a sunny week in May 2006, it became a place known not only for crusades and holy wars, but also for evidence-based battles followed by compromise and consensus, in true OMERACT style.

The executive has been slightly overwhelmed with the sheer scope of activities growing under the OMERACT umbrella. Twenty-two separate high quality activities took place, with a nice mix of “generic-measurement methodology” and “disease oriented” topics. Under the leadership of numerous (co-)chairs, 22 groups worked hard to present the science discussed at the conference.

The growth of OMERACT means adaptation and change. OMERACT 8 saw both the small special interest group meetings and the large workshops run in parallel.

Several special interest groups also participated in a plenary “Superworkshop” by providing input from their specialized area into the generic concept of surrogate endpoints. With EULAR’s support, the fellows/young researchers were back, attending a special preconference training day on outcome measurement before joining the other participants. The fellows successfully counteracted the impression of greying or thinning hair-do’s more prevalent among some of our senior members.

OMERACT has always been an initiative built by the participants. The executive has decided to take this to a new level by initiating discussions on a new and more participatory structure of governance: a broadly based “OMERACT faculty” that will become the new Steering Committee. All current (co-)chairs as well as all participants attending at least 2 meetings and the Scientific Advisory Committee were invited to discuss this at a lunch meeting during the conference, and these discussions will continue.

Apart from clinician scientists, 2 groups of “end users” of consensus outcome measures deserve special mention: patients and Industry. Very early on, OMERACT recognized the need for input from patients. Patients have actively participated in OMERACT activities since 2000, preparing for the first special module that took place during OMERACT 6 (2002). We believe their input is essential to decide on the right measurement tools, and their dedication to the process is an example for us all.

OMERACT has always sought constructive engagement with Industry. Industry supports OMERACT financially through a Business Advisory Committee. Corporate Members of this committee consult with the Executive on the agenda for the meetings, and send a limited number of delegate scientists to each meeting. In this way we hope that the consensus reached on outcome measures also includes measurement concerns raised from that perspective, and in turn that recommendations are rapidly taken up in trial design.

Some things do not change: all activities were participatory and interactive. Its outcome was unknown until the end: the conference site enabled hard work, but also fun. The conference proceedings will be printed in 4 installments in the coming issues of The Journal of Rheumatology, and be freely available for download through a link on our website: www.omeract.org.

Part 1, featured in this issue, focuses on Biomarkers and Surrogate Endpoints, the activities that took place in and around the Superworkshop mentioned above. Part 2, Imaging, continues on this topic, while grouping together all the articles on imaging. Part 3, Outcome Measures, features articles on the core set of measures for psoriatic arthritis and measurement of fatigue in rheumatoid arthritis, as well as several reports from special interest groups. Part 4, Workshops and Special Interest Groups closes this cycle of OMERACT with reports of the Vasculitis, Fibromyalgia, and Drug Safety Workshops, plus the remaining special interest groups. Please enjoy!

MAARTEN BOERS, MD, MSc, PhD,
Chair, OMERACT 8,
Department of Clinical Epidemiology and Biostatistics,
VU University Medical Center,
Amsterdam, The Netherlands

VIBEKE STRAND, MD,
Biopharmaceutical Consultant,
Adjunct Clinical Professor, Immunology/Rheumatology,
Stanford University,
Portola Valley, California, USA

LEE S. SIMON, MD,
Beth Israel Deaconess Medical Center,
Harvard Medical School,
Boston, Massachusetts, USA

PETER TUGWELL, MD, MSc, FRCP,
Department of International Health,
University of Ottawa,
Ottawa, Ontario, Canada

PETER BROOKS, MD, FRACP,
Faculty of Health Sciences,
University of Queensland,
Brisbane, Australia